ArticleFrontiers in immunology2023

Efficacy and safety of programmed cell death receptor 1 inhibition-based regimens in patients with pediatric malignancies: the real-world study in China.

Ye Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.